HUTCHMED (HCM) vests 19,913 LTIP shares for CEO Dr. Weiguo Su
Rhea-AI Filing Summary
HUTCHMED (China) Limited reports the vesting of non-performance based awards under its Long Term Incentive Plan. On March 13, 2026, awards granted on March 13, 2024 to Dr. Weiguo Su, Executive Director, Chief Executive Officer and Chief Scientific Officer, vested into 19,913 ordinary shares.
The vesting occurred at a price of nil and outside a trading venue, reflecting equity-based compensation rather than a market transaction. The notification is made in line with UK Market Abuse Regulation requirements and relates to ordinary shares of US$0.10 par value.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2026
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. | | Description |
| | |
Exhibit 99.1 | | Announcement relating to vesting of awards under the long term incentive plan |
| | |
| | |
| | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUTCHMED (CHINA) LIMITED | |
| | |
| | |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |
Date: March 16, 2026
3
Exhibit 99.1
Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 16, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on March 13, 2024 to the following person discharging managerial responsibilities were vested on March 13, 2026:-
Award Holder | | Number of ordinary shares |
| | |
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) | | 19,913 |
The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.
Dr Weiguo Su
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name | Dr Weiguo Su | |||
2 | Reason for the notification | ||||
a) | Position/status | Executive Director, Chief Executive Officer and Chief Scientific Officer | |||
b) | Initial notification/Amendment | Initial notification | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | HUTCHMED (China) Limited | |||
b) | LEI | 2138006X34YDQ6OBYE79 | |||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.10 Ordinary Share with DI ISIN: KYG4672N1016 | |||
b) | Nature of the transaction | Vesting of awards granted on March 13, 2024 under HUTCHMED's LTIP | |||
c) | Price(s) and volume(s) | | | | |
| Price(s) | Volume(s) | | ||
| Nil | 19,913 ordinary shares | | ||
| | | | ||
d) | Aggregated information — Aggregated volume — Price | N/A | |||
e) | Date of the transaction | 2026-03-13 | |||
f) | Place of the transaction | Outside a trading venue | |||
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| |
Media Enquiries | |
FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| |
Panmure Liberum | Nominated Advisor and Joint Broker |
Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| |
Cavendish | Joint Broker |
Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| |
Deutsche Numis | Joint Broker |
Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |